Value of the TXMD rightsAn interesting thing I caught:
https://seekingalpha.com/pr/17537922-therapeuticsmd-theramex-enter-exclusive-license-supply-agreement-commercialize-bijuva-imvexxy TherapeuticsMD just outlicensed the rights to Imvexxy and Bijuva for the rest of the world (ex. US, Canada, and Israel), for which it received an upfront payment of ~$16 million USD. If you'll recall, Knight got the rights to those products in Canada and Israel for essentially free as the deal was just that Knight would buy shares of TXMD.
The two caveats are that TXMD shares are down a lot since investing and Theramex is getting a much bigger market opportunity. But Still an exmaple of the discliplined deal maker Goodman is.